在住院COVID-19患者中使用甲基普雷迪尼索隆:一项回顾性研究
Nur Fatin Najwa Azemi1,2, Farida Islahudin1, Rahela Ambaras Khan2
1Centre for Quality Management of Medicines, Faculty of Pharmacy, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Journal of pharmaceutical policy and practice
|April 19, 2024
概括
在住院COVID-19患者中基于体重的甲基普雷迪尼索隆剂量与较低的住院死亡率有关. 对COVID-19治疗的最佳甲基prednisolone疗法进行进一步的研究是有必要的.
科学领域:
- 医学研究 医学研究
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 甲基普雷迪尼索隆在治疗2019年新冠肺炎疾病 (COVID-19) 中显示有好处.
- 甲基普雷迪尼索隆的最佳剂量,持续时间和时间尚不清楚.
- 关于各种甲基前尼索隆治疗方案的比较结果的数据有限.
研究的目的:
- 在住院COVID-19患者中调查不同甲基普雷迪尼索隆治疗方案的结果.
- 评估各种剂量策略对临床结果和安全性的影响.
- 为优化COVID-19的甲基普雷迪尼索隆疗法提供见解.
主要方法:
- 住院成人COVID-19患者的回顾性队列研究.
- 纳入标准:2021年6月至8月期间入院并接受甲基前尼索隆治疗.
- 评估结果:住院死亡率,30天死亡率,临床疗效 (CRP,TWBC,氧气需求) 和安全性.
主要成果:
- 在甲基prednisolone剂量 (p=0.023) 中观察到在医院死亡率的显著差异.
- 基于体重的剂量 (1-2 mg/kg/day) 与固定剂量 (250-500 mg/day) 相比,与较低的住院死亡率有关.
- 治疗方案之间没有发现30天死亡率,临床疗效或安全性的显著差异 (p>0.05).
结论:
- 对于住院COVID-19患者,应考虑基于体重的甲基普雷迪尼索隆剂量.
- 这种方法与减少住院死亡率的积极结果有关.
- 需要进一步的研究来确认最佳的甲基普雷迪尼索隆剂量策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
COPD: Management Using Bronchodilators and Corticosteroids
198
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
198
Pneumonia IV: Management
324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324


